PeproTech Inc.
Originally published online as doi:10.1189/jlb.0803400 on March 12, 2004

Published online before print March 12, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0803400v1
75/6/1010    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ten Hove, T.
Right arrow Articles by te Velde, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ten Hove, T.
Right arrow Articles by te Velde, A. A.
(Journal of Leukocyte Biology. 2004;75:1010-1015.)
© 2004 by Society for Leukocyte Biology

Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease

Tessa ten Hove*, F. Olle The*, Marloes Berkhout*, Joost P. Bruggeman*, Florry A. Vyth-Dreese{dagger}, J. Frederik M. Slors{ddagger}, Sander J. H. van Deventer§ and Anje A. te Velde*,1

* Laboratory for Experimental Internal Medicine,
{dagger} VU Medical Center, Departments of
§ Gastroenterology and Hepatology and
{ddagger} Surgery, Academic Medical Centre, Amsterdam, The Netherlands

1 Correspondence: Laboratory of Experimental Internal Medicine, H2-256, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. E-mail: a.a.tevelde{at}amc.uva.nl

The importance of CD45RB expression on T cells was already shown in mice where CD45RBhigh expression determines pathogenic potential. In this study, we analyzed the expression of CD45RA, CD45RB, and CD45RO on CD4+ T lymphocytes in the intestinal mucosa and in the circulation of patients with inflammatory bowel disease (IBD). In addition, we studied the cytokine profile of these cells. In the circulation, virtually all CD4+CD45RBhigh T cells expressed the naive marker CD45RA, and circulating CD4+CD45RBlow cells expressed the memory marker CD45RO in IBD patients and a control patient population. In contrast, the intestinal CD4+ CD45RBhigh T cells are in normal controls for 90% CD45RO+. However, in IBD, 27.7% [Crohn’s disease (CD)] and 49% [ulcerative colitis (UC)] of the intestinal CD4+ CD45RBhigh T cells are CD45RA+. This special CD4CD45RA+ T cell in IBD can be found in the lamina propria as well as in lymphoid follicles (confocal laser-scanning microscopy). The CD4+CD45RBhigh T lymphocytes produce significantly less interleukin (IL)-10 and IL-4 and produce more tumor necrosis factor {alpha} than CD45RBlow T lymphocytes in control patients. CD4+CD45RBlow T cells from IBD patients produced less IL-10 than CD4+CD45RBlow T lymphocytes of controls, and interferon-{gamma} production by both T lymphocyte subsets was decreased in IBD. These data indicate that CD and UC are characterized by an influx of CD4+CD45RBhigh T lymphocytes. These CD4+CD45RBhigh T lymphocytes seem to be important in the pathogenesis of IBD, as they produce more proinflammatory cytokines and less anti-inflammatory cytokines compared with CD4+CD45RBlow T lymphocytes.

Key Words: cytokines • inflammation • human




This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. A. Cox, G. Shi, H. Yin, B. P. Vistica, E. F. Wawrousek, C.-C. Chan, and I. Gery
Both Th1 and Th17 Are Immunopathogenic but Differ in Other Key Biological Activities
J. Immunol., June 1, 2008; 180(11): 7414 - 7422.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Fukata, K. Breglio, A. Chen, A. S. Vamadevan, T. Goo, D. Hsu, D. Conduah, R. Xu, and M. T. Abreu
The Myeloid Differentiation Factor 88 (MyD88) Is Required for CD4+ T Cell Effector Function in a Murine Model of Inflammatory Bowel Disease
J. Immunol., February 1, 2008; 180(3): 1886 - 1894.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. H. Chidlow Jr., W. Langston, J. J.M. Greer, D. Ostanin, M. Abdelbaqi, J. Houghton, A. Senthilkumar, D. Shukla, A. P. Mazar, M. B. Grisham, et al.
Differential Angiogenic Regulation of Experimental Colitis
Am. J. Pathol., December 1, 2006; 169(6): 2014 - 2030.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. Rutgeerts, W. J. Sandborn, B. G. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. B. Hanauer, G. R. Lichtenstein, et al.
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
N. Engl. J. Med., December 8, 2005; 353(23): 2462 - 2476.
[Abstract] [Full Text] [PDF]